Roche Holding AG operates in the pharmaceuticals and diagnostics businesses across Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. It provides pharmaceutical solutions in therapeutic areas including anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune conditions, neurological disorders, ophthalmology, respiratory disorders, and transplantation. The company also offers in vitro diagnostic tests for diseases such as cancer, diabetes, Covid-19, hepatitis, and human papillomavirus, along with diagnostic instruments and digital health solutions. Roche has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. Founded in 1896, the company is based in Basel, Switzerland.
CHMP Backs Roche's Ocrevus for Children and Teens With Relapsing MS
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of Roche's Ocrevus, or ocrelizumab, intravenous infusion for patients aged 10 years and older with relapsing forms of multiple sclerosis, making it the first high-efficacy anti-CD20 treatment option for people with MS as young as 10 years old. The positive opinion rests on the Phase III OPERETTA 2 study, in which Ocrevus was non-inferior to fingolimod, the current standard treatment in paediatric MS, at controlling relapses and reduced the risk of relapses by 48% compared with fingolimod. In the same trial Ocrevus was superior at reducing brain inflammation, with significant reductions in new or enlarging T2 lesions of 48% and gadolinium-enhancing active T1 lesions of 87%, and its safety profile in children and teens was consistent with that seen in adults, with no patients stopping treatment due to side effects. The U.S. FDA approved Ocrevus for paediatric RMS patients in May 2026, and a final decision from the European Commission is expected in the near future. At least 40,000 children and adolescents are living with MS worldwide, with roughly one-third in Europe.
Genentech and Roche Open Boston R&D Innovation Center
Genentech, a member of the Roche Group, and Roche announced the grand opening of the Roche Genentech Innovation Center Boston, a 95,000 square foot facility at Harvard's Enterprise Research Campus in Allston under a 10-year lease with capacity for up to 500 people. The center focuses on cardiovascular, renal and metabolic diseases, bringing together scientists across discovery research, clinical development, artificial intelligence and data science in an end-to-end research environment spanning early-stage discovery through late-stage clinical development. The Innovation Center is part of Roche and Genentech's $50 billion investment in U.S. manufacturing and R&D, building on recent investments and manufacturing milestones in Holly Springs, North Carolina, and Hillsboro, Oregon. Roche and Genentech have approximately 25,000 employees in the United States, with 15 R&D centers and 13 manufacturing sites. Roche CEO Dr. Thomas Schinecker said the investment in Boston is an important part of the commitment to expand the U.S. manufacturing and R&D footprint, while Genentech CEO Ashley Magargee said the center places scientists at the heart of one of the world's most dynamic research communities.
Roche's Lunsumio Combo Meets Primary Endpoint in Phase III CELESTIMO Follicular Lymphoma Study
Roche announced that the phase III CELESTIMO study of Lunsumio, also known as mosunetuzumab, in combination with Revlimid, or lenalidomide, met its primary endpoint in people with relapsed or refractory follicular lymphoma who had received at least one prior line of treatment. The Lunsumio regimen produced a statistically significant and clinically meaningful improvement in progression-free survival versus MabThera/Rituxan, or rituximab, plus Revlimid, while overall survival data were immature at the interim analysis. The safety profile of Lunsumio plus Revlimid was consistent with the known profiles of the individual medicines, with no new safety signals reported. CELESTIMO is the confirmatory study required to convert Lunsumio monotherapy's accelerated approval and conditional marketing authorization for third-line or later follicular lymphoma into full approval, and it is also intended to support an indication in second-line or later disease. Roche plans to submit the data to health authorities and present it at an upcoming medical conference. Separately, Lunsumio is approved as a fixed-duration monotherapy for third-line or later relapsed or refractory follicular lymphoma in both intravenous and subcutaneous formulations, and in June 2026 the FDA accepted Roche's supplemental biologics license application for Lunsumio VELO in combination with Polivy for relapsed or refractory large B-cell lymphoma, with a decision expected on Feb. 9, 2027.
Dualitas Therapeutics and Roche Launch Bispecific Antibody Collaboration Worth Up to $1 Billion
Dualitas Therapeutics announced a research collaboration and license agreement with Roche to discover and develop novel bispecific antibodies for immunology and inflammation diseases using Dualitas' DualScreen Bispecific Discovery Engine. Under the deal, Dualitas will functionally screen more than 300,000 novel bispecific combinations, which the company describes as one of the largest-scale bispecific discovery endeavors, while Roche will handle all subsequent preclinical development, regulatory, manufacturing and commercial activities. Dualitas will receive $36.5 million in upfront payments and is eligible for research, development and commercial milestone payments plus tiered royalties for a potential total deal value of up to $1 billion. Forbes Huang, co-founder, chief operating officer and chief business officer of Dualitas, called the partnership a first-of-its-kind collaboration to functionally screen and develop novel proximity bispecific antibodies at a scale previously unachievable. Boris L. Zaïtra, Head of Corporate Business Development at Roche, said bispecific antibodies remain central to Roche's portfolio strategy across many disease areas, and Karim Dabbagh, chief executive officer and board member of Dualitas, said the collaboration underscores the potential of the company's technologies to identify bispecific antibodies that harness novel proximity mechanisms.
Study finds Trump's Medicare drug price crackdown risks pushing drugmakers to raise prices or withdraw medicines worldwide
A new study published in the medical journal The Lancet suggests that the Trump administration's efforts to cut U.S. drug spending could give pharmaceutical companies an incentive to raise prices or reduce sales of medicines in other countries around the world to offset lost revenue in the U.S. market. The Trump administration wants prices for drugs under the federal Medicare health program to align with levels in other wealthy countries, but researchers found that for about three in four of the medicines studied, if companies had to cut the prices they charge Medicare to match those of cheaper reference countries, the revenue lost in the U.S. would exceed the drug's entire sales in the reference country. The study analyzed 195 patented drugs, accounting for a total of 87.9 billion dollars in Medicare spending in 2024, comparing them with drug prices in 19 reference countries. It found that aligning the prices Medicare pays with those of the reference countries would save the two pilot programs the U.S. government uses to test the measure about 11.6 billion dollars. But if the 17 drugmakers that struck separate pricing agreements with the White House were exempted, the savings would fall to just 3.3 billion dollars. The effects are already emerging: Astellas Pharma said it was able to negotiate a higher price for a new eye disease treatment in Japan this year, while Chris Viehbacher, chief executive of Biogen, said the company would launch Zurzuvae, a treatment for postpartum depression, in only a few European countries, and Roche Holding said it may not launch a new oral breast cancer drug, which has not yet been approved in Switzerland, the company's home country.
Roche Partner MediLink Reports Phase III Win for Tam-Peli in Relapsed SCLC
Roche announced that its collaborator MediLink released interim results from the randomized phase III TAISHAN-302 trial showing that Tam-Peli, also known as tambotatug pelitecan or YL201, beat topotecan in Chinese patients with relapsed small-cell lung cancer who progressed after prior platinum-based chemotherapy with or without a PD-L1 inhibitor. The trial met its primary endpoint of overall survival, with Tam-Peli reducing the risk of death by 54 percent, with median overall survival of 13.3 versus 9.4 months and a stratified hazard ratio of 0.46 at a p-value below 0.0001. Tam-Peli also extended median progression-free survival to 7.4 months from 2.8 months and achieved a confirmed objective response rate of 59.1 percent versus 9.7 percent. The results are being presented as a Late-Breaking Abstract during a Presidential Presentation at the IASLC 2026 World Conference on Lung Cancer in Seoul with simultaneous publication in The New England Journal of Medicine, and China's Center of Drug Evaluation has accepted the New Drug Application for filing. Roche, which holds development, manufacturing and commercialization rights for Tam-Peli worldwide outside mainland China, Hong Kong and Macau under a January 2026 exclusive licensing agreement with MediLink Therapeutics, said the data support plans to rapidly initiate global phase III trials.
Amgen and AstraZeneca Lung Cancer Combo Meets Survival Goal in Phase III Study
Amgen and AstraZeneca announced positive results from a phase III study of Imdelltra, or tarlatamab, in combination with AstraZeneca's Imfinzi, or durvalumab, in certain patients with extensive-stage small-cell lung cancer. The trial, called DeLLphi-305, tested the combination against Imfinzi alone as a first-line maintenance treatment for patients whose cancer had not progressed after induction with Imfinzi plus platinum chemotherapy and etoposide. The study met its primary endpoint of overall survival and a key secondary endpoint of progression-free survival, though neither company provided numerical data and both said no new safety concerns were identified. DeLLphi-305 is sponsored by Amgen, with partial funding and Imfinzi supplied by AstraZeneca. AstraZeneca estimates that roughly 195,000 people globally will be treated for extensive-stage small-cell lung cancer in 2026, and the companies say small-cell lung cancer accounts for about 15% of lung cancers, with about two-thirds of those patients diagnosed with the extensive-stage form. If approved, the Imfinzi-Imdelltra combination would enter a first-line maintenance market where the FDA in October 2025 approved Jazz Pharmaceuticals' Zepzelca, or lurbinectedin, with Roche's Tecentriq, or atezolizumab, based on the IMforte study, which showed a 46% reduction in the risk of disease progression or death and a 27% reduction in the risk of death versus Tecentriq alone. Imdelltra, a bispecific T-cell engager approved in 2024 for second-line extensive-stage small-cell lung cancer, posted global sales of $546 million in the first half of 2026, up from $215 million a year earlier, while Imfinzi's first-half 2026 revenues rose 31% year over year to $3.55 billion.
Roche Wins FDA Priority Review for Enspryng in Rare MOGAD Disorder
Roche announced that the FDA has accepted its supplemental biologics license application seeking approval of Enspryng, also known as satralizumab, for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease, or MOGAD, and granted the application a priority review with a decision expected on Jan. 10, 2027. If approved, Enspryng would become the first and only disease-modifying therapy for MOGAD, a rare autoimmune disease of the central nervous system that can cause unpredictable attacks affecting the optic nerves, spinal cord or brain and for which there are currently no approved treatments. The FDA's acceptance was based on positive data from the phase III METEOROID study, which met its primary endpoint, showing that treatment with Enspryng reduced the risk of a new MOGAD relapse by 68% compared with placebo, and that at 48 weeks 87% of patients treated with Enspryng remained relapse-free compared with 67% in the placebo arm. Separately, the European Medicines Agency has validated Roche's application for Enspryng in MOGAD, with a decision from the European Commission expected in the third quarter of 2027. Enspryng is currently approved in several countries for the treatment of neuromyelitis optica spectrum disorder, including the European Union and the United States, and Roche is also evaluating it in additional neurological autoimmune and inflammatory disorders, with the FDA having accepted and granted priority review in June 2026 to a separate sBLA seeking label expansion for thyroid eye disease and a final decision expected on Oct. 15, 2026.
Novartis Faces $3 Billion MS Opportunity and Key Risks
Novartis AG could be staring at a $3 billion annual peak-sales opportunity in multiple sclerosis if its drug remibrutinib successfully advances through the regulatory process and gains meaningful market share. Bank of America estimates that remibrutinib could generate about $3 billion in peak annual sales in multiple sclerosis alone and potentially more than $10 billion across all indications. The comments follow encouraging results from the REMODEL-1 and REMODEL-2 Phase 3 trials announced on September 2, which showed that remibrutinib reduced relapse activity and met primary endpoints in patients with relapsing multiple sclerosis. The global MS therapeutics market is expected to grow at a 5.9% compound annual growth rate to approximately $38.6 billion by 2030, and Novartis already has a major presence through Kesimpta, which generated approximately $1.42 billion in second-quarter sales, up 32% year over year. However, risks include potential slowdown in Kesimpta growth, competition from Roche's BTK inhibitor, and the uncertainty of regulatory approval and physician adoption. Hedge fund interest is rising, with 38 funds holding stakes in the second quarter, up from 31 in the first quarter, while short interest remains low at approximately 0.26% of public float.
Ulcerative Colitis Market to Reach $9.4B by 2036, Late-Stage Drugs Advance
DelveInsight projects the ulcerative colitis market across the seven major markets—the US, EU4, UK, and Japan—will grow from approximately USD 9.4 billion in 2025 at a CAGR of 7.6% through 2036, driven by novel targeted therapies and a robust pipeline of late-stage candidates. Among these, Abivax's obefazimod, a first-in-class oral miR-124 enhancer, met its primary endpoint in Phase III ABTECT induction studies, with a pooled placebo-adjusted clinical remission rate of 16.4% at Week 8. Merck's tulisokibart, acquired via Prometheus Biosciences, achieved clinical remission in the Phase 3 ATLAS-UC study, while Roche's afimkibart, from its $7.1 billion Telavant acquisition, showed a 35% remission rate in Phase IIb TUSCANY-2. Johnson & Johnson and Protagonist Therapeutics' icotrokinra, a first-in-class oral IL-23 receptor antagonist, met its primary endpoint in the Phase 2b ANTHEM-UC trial, and Teva and Sanofi's duvakitug, backed by a $400 million Blackstone funding deal, is in Phase III. These therapies target unmet needs in moderate-to-severe disease, with the market shifting toward IL-23 inhibitors and oral advanced therapies, though biosimilars and established anti-TNFs remain widely used.
Roche Gets FDA Clearance for Alzheimer's Blood Test
Roche Holding announced a collaboration with Treeline Biosciences to study combination immunotherapies for B-cell lymphomas, and received FDA clearance for its Elecsys pTau217 blood test, the first single biomarker assay to help rule in and rule out amyloid pathology in Alzheimer's disease. The test is intended to support earlier and more accessible Alzheimer's diagnostic assessments. Roche, a pharmaceuticals and diagnostics group with a CHF285.2 billion market cap, is expanding its oncology pipeline through partnerships and its diagnostics portfolio with neurology assays. The lymphoma partnership and the blood test clearance align with Roche's strategy of combining pipeline breadth and diagnostics depth, though the company faces competition from Novartis, Bristol Myers Squibb, Abbott, and Siemens Healthineers.
Treeline and Roche Partner to Test TLN-121 with Bispecific Antibodies
Treeline Biosciences has announced a clinical trial collaboration and supply agreement with Roche to evaluate its BCL6 degrader TLN-121 in combination with Roche's CD20xCD3 T-cell-engaging bispecific antibodies glofitamab and mosunetuzumab for B-cell lymphomas. Under the agreement, Treeline will sponsor and conduct a Phase 1 dose escalation and expansion study, with Roche supplying the antibodies for specific expansion cohorts, and combination dosing is expected to begin in the fourth quarter of 2026. Preclinical data presented by Treeline show that TLN-121 enhances anti-tumor activity when combined with these bispecific antibodies or with CD19 CAR-T cell therapy, including complete regressions in mouse models of diffuse large B-cell lymphoma. Treeline's CEO Josh Bilenker expressed excitement about building on the progress of these bispecific antibodies in collaboration with Roche.
Roche Commits $75 Million in Blood-Cancer Deal Worth Up to $1.53 Billion
Roche has committed $75 million upfront for global rights to Simcere Pharmaceutical's experimental blood-cancer drug SIM0660, in a deal that could be worth up to $1.53 billion. The Swiss pharmaceuticals and diagnostics giant will gain exclusive development, manufacturing, and commercialization rights outside Simcere's retained markets, with up to $1.455 billion in potential milestone payments and tiered royalties reaching double-digit percentages. The drug remains preclinical, and Roche's upfront payment represents just 4.9% of the deal's maximum value, keeping the early financial risk low. Roche's U.S.-quoted shares fell to $53.55 on Tuesday, trading 30.01% above the GF Value of $41.19, indicating a premium valuation while the drug is far from commercialization.
Roche's Columvi Gains Singapore Subsidies for Relapsed DLBCL
Roche's Columvi (glofitamab) will be added to Singapore's Cancer Drug List and Medication Assistance Fund on 1 September 2026, providing subsidised access for eligible patients with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplant and have received at least one prior therapy. Under the Medication Assistance Fund, eligible Singapore Citizens and Permanent Residents will receive subsidies of up to 75% and 20% respectively at public healthcare institutions. The treatment, used in combination with gemcitabine and oxaliplatin, offers a new off-the-shelf option alongside existing therapies such as CAR-T cell therapy and chemotherapy. In the pivotal phase III STARGLO study, overall survival was twice as long for patients treated with Columvi plus GemOx versus rituximab plus GemOx, at 25.5 months versus 12.9 months, with 38% of patients remaining in remission at 30 months compared to 15% in the comparator arm. Lymphoma is the fourth most common cancer among men and fifth among women in Singapore, with DLBCL accounting for roughly 30% of local lymphoma diagnoses.
Alnylam Pharmaceuticals presented new data at the European Society of Cardiology Congress 2026, reinforcing the strength of RNAi-powered TTR silencing across ATTR-CM patient populations and treatment settings. A late-breaking prespecified subgroup analysis of the HELIOS-B Phase 3 trial showed that vutrisiran provided consistent clinical benefit on all-cause mortality and recurrent cardiovascular events in patients with or without tafamidis use at baseline, among 654 randomized patients, 40% of whom were on tafamidis. Additional post hoc analyses highlighted vutrisiran's positive impact on multisystemic manifestations, including a 25% less decline in intrinsic capacity and a 52% reduction in risk of decline. A pooled analysis of 1,402 patients across four Phase 3 studies of vutrisiran and patisiran showed consistent treatment effects across sexes. New subgroup data from the KARDIA-3 Phase 2 study of zilebesiran suggested potential for enhanced blood pressure control, particularly in patients on background diuretics with elevated systolic BP. These findings support the ongoing Phase 3 ZENITH trial for zilebesiran, co-developed with Roche.
Roche Secures FDA Approval for Alzheimer's Blood Test
Roche Holding has received FDA approval for its Elecsys pTau217 blood test for Alzheimer's disease in the U.S., a diagnostic designed to identify amyloid pathology from a blood sample and widen access to dementia testing across American labs. The FDA also cleared expanded use of Roche's PATHWAY HER2 and VENTANA HER2 Dual ISH tests in metastatic gastroesophageal cancers, broadening options for HER2 testing in cancer care. These approvals highlight how diagnostics and healthcare AI are reshaping clinical workflows, and they fit into Roche's broader strategy of expanding its companion diagnostics portfolio. Investors should watch how quickly U.S. labs adopt the Elecsys pTau217 test across the 4,500 installed cobas instruments, as well as reported testing volumes for the HER2 assays, to gauge the impact on Roche's diagnostics growth.
Qiagen's Parse Biosciences Hit with $4.8M Jury Award in Patent Dispute
A Delaware federal jury has ordered Qiagen subsidiary Parse Biosciences to pay more than $4.8 million in damages for infringing three patents licensed by 10x Genomics' Scale Biosciences unit from Roche. The jury also rejected Parse's claims that the patents were invalid, affirming they are valid and enforceable. The damages are based on a 14% royalty rate on sales of infringing products from February 2021 through June 30, 2026. 10x Genomics said it will seek a permanent injunction and additional awards for attorneys' fees and enhanced damages in post-trial proceedings.
BioNTech halts cancer vaccine trial, Arcturus and Moderna fall
Messenger RNA drug developers Arcturus Therapeutics and Moderna traded lower on Friday after BioNTech halted a mid-stage trial for its mRNA-based cancer vaccine BNT122, developed with Roche, due to efficacy concerns. Arcturus lost more than 7%, while Moderna fell for a third consecutive session, weighed down by the trial setback and a new $2.6B convertible note offering. Last week, Moderna shares had climbed to a post-pandemic peak after a late-stage trial win for its own mRNA cancer shot, Intismeran, developed with Merck. BioNTech's BNT122-01 study enrolled patients with surgically removed colorectal cancers, whereas Moderna's Phase 3 INTerpath-001 trial targeted resected melanoma. BioNTech said it discontinued the trial after a data safety monitoring board noted a numerical imbalance in overall survival between treatment arms, determining the trial was unlikely to reach its efficacy outcome. Scotiabank analyst Louise Chen argued the decision bodes well for Merck, while BMO Capital Markets analyst Evan David Seigerman called it a clear setback but noted the negative read-through is not necessarily one-to-one across indications.
The global cytotoxic drugs market is projected to grow from $16.21 billion in 2026 to $21.06 billion by 2031, at a compound annual growth rate of 5.37%, according to a new report from ResearchAndMarkets.com. Rising cancer incidence, earlier diagnosis, expanded reimbursement, and growing demand in emerging economies are driving the market. In 2025, the market was valued at $15.38 billion, with parenteral drugs holding a 68.87% share, while oral drugs are expected to grow faster at an 8.79% CAGR. Alkylating agents led with a 30.10% share in 2025, but antimetabolites are forecast to grow fastest at 7.02% CAGR. North America accounted for 42.15% of revenue in 2025, while Asia-Pacific is projected to grow at 10.07% CAGR, supported by China's approval of 228 drugs in 2024, 37% of which were antineoplastics. Key players include Pfizer, Roche, Novartis, AstraZeneca, and Sanofi.
Roche's Vabysmo Shows Sustained Two-Year Results in PCV
Roche announced new two-year data from the Phase IIIb/IV SALWEEN study showing that Vabysmo (faricimab) significantly improved vision and retinal health in patients with polypoidal choroidal vasculopathy (PCV), a severe subtype of neovascular age-related macular degeneration (nAMD). The study, presented at the 19th Asia-Pacific Vitreo-retina Society Congress, found that patients gained 7.3 letters in best-corrected visual acuity and had a reduction of 127 micrometers in central subfield thickness from baseline averaged over weeks 100 to 108. At year two, 74% of patients had no retinal fluid, and complete regression of polypoidal lesions occurred in 62% of eyes, with inactivation in 86%. More than 60% of patients were on an extended 20-week treatment interval by the end of year two, reducing treatment burden. Vabysmo was well tolerated with a safety profile consistent with its known profile in nAMD. The study enrolled 135 patients from nine Asian markets, including China, Japan, and South Korea.
FDA Clears Lilly-Roche Alzheimer's Blood Test; Healthcare ETFs to Watch
The U.S. Food and Drug Administration has granted clearance to the Elecsys pTau217 blood test, developed by Eli Lilly and Roche, making it the first and only FDA-cleared single-biomarker blood test for Alzheimer's that can both rule in and rule out amyloid-beta pathology using one validated clinical cutoff. With an estimated 7.4 million Americans aged 65 and older currently living with clinical Alzheimer's dementia, a figure projected to nearly double to 13.8 million by 2060, and national care costs expected to reach $409 billion this year, the approval is set to expand the eligible patient pool for disease-modifying therapies, potentially boosting the global Alzheimer's DMT market to $13.1 billion by 2030. Healthcare ETFs such as the State Street Health Care Select Sector SPDR ETF, iShares Global Healthcare ETF, VanEck Pharmaceutical ETF, and iShares Neuroscience and Healthcare ETF offer diversified exposure to these pharmaceutical giants and the growing Alzheimer's treatment market.
Roche gets FDA approval for HER2 companion diagnostics in gastroesophageal cancer
Roche announced that the FDA has approved expanded use of its PATHWAY HER2 (4B5) and VENTANA HER2 Dual ISH DNA Probe Cocktail tests as companion diagnostics to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma, including gastric, gastroesophageal junction, and esophageal adenocarcinoma, who may be eligible for treatment with Jazz Pharmaceuticals' ZIIHERA. This approval broadens the patient population eligible for HER2-targeted therapy, as previously no tests were approved to determine HER2 status in esophageal cancer. The tests, already widely used in breast and gastric cancers, are now part of Roche's comprehensive HER2 diagnostic portfolio, supporting personalized treatment approaches for this hard-to-treat disease.
Medication Adherence Market to Reach $15.35 Billion by 2035
The global medication adherence market is projected to grow from USD 6.08 billion in 2026 to USD 15.35 billion by 2035, at a compound annual growth rate of 10.92%, according to a new report from ResearchAndMarkets.com. The market's expansion is driven by rising chronic disease prevalence, an aging population, and adoption of digital health technologies. Software-centric solutions currently account for about 65% of the market, while hardware-centric solutions are expected to see faster growth. North America remains the largest regional market, with Asia-Pacific growing fastest. Key players include Medtronic, Roche, Insulet, Ypsomed, and 13 others.
Genentech to invest $750 million in Oregon manufacturing facility
Genentech, a member of the Roche Group, announced plans to invest approximately $750 million in a new device fill-finish manufacturing facility at its 75-acre campus in Hillsboro, Oregon. The investment will double the size of the existing facility and is expected to create 250 high-wage manufacturing jobs and approximately 200 construction jobs, with commercial operations expected to begin in 2031. The new facility will support the manufacturing of advanced drug delivery devices, such as pre-filled syringes and autoinjectors, and is designed for flexible high- and low-volume device filling across Roche and Genentech's portfolio. The Hillsboro investment follows the recent topping out of Genentech's new manufacturing facility in Holly Springs, North Carolina, which will support global production of metabolic medicines including next-generation obesity treatments.
Labcorp Raises Guidance, Completes Buyback, and Expands Oncology Testing
Labcorp reported higher second-quarter and year-to-date earnings, raised its 2026 revenue growth guidance, completed a large share repurchase program, and made Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay available nationwide to guide prostate cancer treatment decisions. The company also recently received FDA approval for its PGDx elio tissue complete CDx for advanced melanoma. These moves reinforce Labcorp's role as a major companion diagnostics provider and signal management confidence through upgraded guidance and sustained buybacks. The PTEN assay rollout and upgraded 2026 guidance support a near-term catalyst around mix shift into precision oncology, though risks such as potential PAMA-related reimbursement cuts and pricing pressure in core lab services remain.
The Swiss market ended firmly higher on Wednesday, with the benchmark SMI gaining 73 points or 0.6% to close at 12,333.93. Roche Holding surged about 5.8% after announcing that a new weight-loss pill under development achieved positive results in an early stage clinical trial. Swatch Group added nearly 2.5% and Nestle rose 1.1%, while VAT Group dropped 5.27% and Logitech International fell 2.39%.
ChemoMetec and Roche Diagnostics sign collaboration agreement for bioprocess monitoring connectivity
ChemoMetec and Roche Diagnostics have entered a collaboration agreement to develop a connection kit linking the Roche Cedex® Bio Analyzer and the ChemoMetec Xcytomatic® 30 cell counting analyzer. The agreement follows a Letter of Intent signed in February 2026 and covers both development and subsequent commercialization of the connectivity solution. Roche will design the connection kit and handle verification and validation, aiming for seamless hardware and software integration between the two instruments. The companies will jointly promote the combined solution while each remains the sole seller of its own analyzers.
Prothena reports second quarter 2026 financial results and updates cash guidance
Prothena Corporation reported its second quarter 2026 financial results, posting a net loss of $18.6 million and updating its year-end cash guidance to approximately $259 million at the midpoint. The company had $289.1 million in cash, cash equivalents and restricted cash as of June 30, 2026, and no debt. The updated cash guidance reflects shares repurchased through July 30, 2026, under its up to $100 million share repurchase program. Prothena also highlighted the publication of Phase 2b PADOVA trial results for prasinezumab in The Lancet and ongoing Phase 3 trials by partners Roche and Novo Nordisk, with potential aggregate future milestone payments of up to approximately $3 billion plus royalties.
Alzheimer's Disease Market Projected to Reach USD 4 Billion in 2025 with 22.7% CAGR Through 2036
The Alzheimer's disease market across the seven major markets was valued at approximately USD 4 billion in 2025 and is projected to expand at a CAGR of 22.7% through 2036, according to DelveInsight. The growth is driven by increasing disease prevalence, broader adoption of disease-modifying therapies, advancements in biomarker-based diagnosis, and a robust late-stage pipeline. Key emerging therapies include Masupirdine from Suven Life Sciences, Roche's Trontinemab, Annovis Bio's Buntanetap, AB Science's Masitinib, Eli Lilly's Remternetug, Axsome Therapeutics' AUVELITY, Biovie's Bezisterim, ALZHEON's Valiltramiprosate, TauRx Therapeutics' Hydromethylthionine mesylate, Bristol Myers Squibb's COBENFY, AriBio's AR1001, Acadia Pharmaceuticals' Remlifanserin, and Cerecin's Tricaprilin. The report highlights six late-stage candidates poised to enter the market, including Masupirdine, Trontinemab, AXS-05, COBENFY, Remternetug, and Buntanetap, each with distinct mechanisms of action and anticipated clinical milestones.
Roche launches two new cyclospora PCR tests amid U.S. outbreak
Roche has launched two new real-time PCR tests for detecting the Cyclospora cayetanensis parasite as an outbreak continues to spread throughout the United States. The LightMix Modular Cyclospora assay provides specific detection of cyclospora only, while the LightMix OneTube Gastro Para 2 assay is a multiplex test that also detects Entamoeba histolytica, Giardia, Dientamoeba fragilis, Cryptosporidium, and Blastocystis. These research-use-only tests expand Roche's cyclospora portfolio, offering laboratories flexible and cost-effective options on the LightCycler 480 and LightCycler PRO instruments. The launch builds on Roche's existing UC-TIB-Gastro-PARA-2 assay, a high-throughput multiplex test for the cobas 5800, 6800, and 8800 systems, and underscores the company's commitment to supporting public health responses to infectious disease outbreaks.
Roche starts breast cancer trial with Evexta Bio using two drug candidates
Roche Holding has entered a clinical collaboration with Evexta Bio to test a combination of rupitasertib and giredestrant in a Phase 1b trial for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer. The trial targets a breast cancer segment with significant unmet medical need and adds to Roche's oncology portfolio. Roche's stock most recently closed at CHF364.7, with a one-year return of 51.2% and a three-year return of 52.3%. The collaboration provides another data point on Roche's research commitments in breast cancer, and upcoming trial results could influence market views on the company's pipeline balance between early- and late-stage assets.
Nurix Therapeutics Receives $10 Million Milestone as Phase 3 Trial Begins
Nurix Therapeutics announced a $10 million milestone payment from Sanofi triggered by the first-in-human trial of an oral STAT6 degrader, bringing total receipts under that collaboration to about $139 million. The company also enrolled the first patient in a pivotal global Phase 3 trial of bexobrutideg for relapsed or refractory chronic lymphocytic leukemia, conducted in partnership with Roche. The Sanofi deal leaves Nurix eligible for roughly $453 million in additional milestones plus potential royalties, while the Roche-partnered study marks a move into registrational testing. Both programs advance Nurix's clinical pipeline in targeted protein degradation and signal that large pharmaceutical partners are committing resources to its drug candidates.
IDEAYA Biosciences Posts Wider Loss and Enters Roche Partnership
IDEAYA Biosciences reported a second-quarter 2026 net loss of US$112.45 million, or US$1.22 per share, bringing its six-month net loss to US$210.99 million, wider than the prior year. The company also advanced its precision oncology pipeline by initiating Part 2 monotherapy expansion for IDE892 and entering a clinical collaboration with Roche to explore combination regimens in MTAP-deleted pancreatic cancer. These developments sharpen near-term catalysts around MTAP-deleted tumors, alongside the anticipated darovasertib and crizotinib NDA filing in the second half of 2026. The stock remains heavily dependent on trial progress and financing confidence rather than quarterly earnings.
Diamond Hill Capital's Mid Cap Strategy highlighted Illumina's strong clinical momentum in its second-quarter 2026 investor letter. The biotechnology company, a leading producer of next-generation sequencing systems, saw its shares rise after reporting better-than-expected clinical growth, while competitor Roche's comparable product launch appeared underwhelming. Illumina closed at $203.01 per share on August 4, 2026, with a one-month return of 6.92% and a 52-week gain of 112.65%. The company has a market capitalization of $30.65 billion and a 52-week trading range between $88.00 and $207.00.
Labcorp Launches First FDA-Approved PTEN Companion Diagnostic for Prostate Cancer
Labcorp announced the nationwide availability of Roche's VENTANA PTEN (SP218) RxDx Assay, the first FDA-approved immunohistochemistry companion diagnostic to detect PTEN protein loss in prostate adenocarcinoma tumors. The assay helps identify patients who may be eligible for treatment with AstraZeneca's TRUQAP in combination with abiraterone acetate and prednisone. PTEN loss is associated with more aggressive disease and reduced benefit from standard therapies, and until now no approved treatments specifically targeted this biology. Labcorp participated in Roche's early access program to ensure Day 1 laboratory readiness, and the test is now available through Labcorp's national network, complementing its comprehensive oncology testing portfolio.
Nurix Therapeutics enrolls first patient in Phase 3 trial of bexobrutideg for relapsed/refractory CLL/SLL
Nurix Therapeutics has enrolled the first patient in its registrational Phase 3 DAYBreak CLL-306 trial evaluating bexobrutideg, a BTK degrader, in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who previously received a covalent BTK inhibitor. The global study, conducted in collaboration with Roche, is designed to demonstrate superiority of bexobrutideg versus the non-covalent BTK inhibitor pirtobrutinib, the current standard of care in this setting. Approximately 620 patients will be randomized 1:1 to receive either bexobrutideg 600 mg orally once daily or pirtobrutinib, with dual primary endpoints of objective response rate and progression-free survival assessed by an independent review committee. This marks the first Phase 3 trial for bexobrutideg and is part of a broader clinical development program that includes a pivotal Phase 2 study and other combination trials.
PTC Therapeutics Reports Record $361 Million Revenue, Raises Full-Year Guidance
PTC Therapeutics reported record quarterly total revenue of $361 million for the second quarter of 2026, driven by strong product sales and royalty income, and raised its full-year 2026 product revenue guidance to between $850 million and $950 million. Product revenue reached $239 million, more than doubling from $118 million in the same quarter last year, while total revenue guidance for the year was increased to a range of $1.18 billion to $1.28 billion. The company's phenylketonuria drug Sephience generated $151 million in global net product revenue, a 21 percent increase from the previous quarter, with 1,647 commercial patients on therapy worldwide as of June 30, 2026. The Duchenne muscular dystrophy franchise contributed $67 million, Translarna net product revenue was $42 million including a Russian government purchase order, Emflaza net product revenue was $25 million, and Evrysdi royalty revenue was $71 million based on Roche's global revenue of approximately $628 million. PTC Therapeutics ended the quarter with $2.23 billion in cash, equivalents, and marketable securities, and management expressed confidence in the potential for cash flow breakeven during 2026.
Roche wins FDA clearance for cobas BV/CV assay and EU backing for Susvimo eye implant
Roche Holding received FDA clearance for its cobas BV/CV assay for diagnosing bacterial vaginosis and Candida vaginitis in the United States, while the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Susvimo, a ranibizumab eye implant, for neovascular age-related macular degeneration in Europe. The cobas BV/CV assay expands Roche's diagnostics portfolio, which already covers infectious disease, oncology, and other high-volume testing areas. Susvimo targets the large ophthalmology segment where treatment burden and visit frequency are key concerns. Roche shares trade at CHF367.9, about 1% above the consensus target of CHF363.9, and are flagged as undervalued, trading roughly 58.5% below Simply Wall St's fair value estimate. The stock has returned 9.5% over the past 30 days.
Trump's new tariffs threaten EU trade deal with pharma and auto exemptions in focus
President Trump announced new U.S. tariffs of 10% to 12.5% on goods from most trading partners, raising questions about the recently negotiated trade deal with the European Union. Seeking Alpha analysts note that pharmaceuticals, heavily imported from the EU and including generic medications, are a key target, potentially affecting firms like Novo Nordisk, Roche, AstraZeneca, and Bayer. The EU deal, locked into EU law with a 15% rate, has not been ratified by the U.S. Senate and could still be changed, with a December 31 deadline for the U.S. to reduce metal tariffs to 15% seen as a critical test. Analysts also warn that additional tariffs on the EU could follow a billion-dollar fine against Alphabet, and that investor focus may shift to Middle East conflicts rather than trade war volatility.
Trump announces phased tariffs up to 200% on generic drug imports
President Donald Trump announced phased tariffs on generic drug imports, starting with zero tariffs for two years from August 1, then rising to 100% in August 2028 and 200% a year later, to push production onshore. Novo Nordisk sued Eli Lilly over ads comparing their GLP-1 weight-loss drugs, alleging misleading efficacy claims. Molina Healthcare shares fell about 11% despite beating second-quarter estimates, as its medical care ratio reached 92.2%. Repligen agreed to acquire BioLife Solutions for about $1.5 billion in a stock-and-cash deal. Roche shares jumped roughly 5% after the company reiterated its 2026 outlook, while Thermo Fisher Scientific raised its full-year guidance following better-than-expected second-quarter results.
Switzerland